FAQ

RAEB with Fibrosis

Known as: RAEB-F 
Refractory anemia with excess blasts associated with significant reticulin fibrosis of the bone marrow.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1985-2016
012319852016

Related topics

Related topics

16 relations
AgranulocytosisAnemiaBone MarrowBone marrow stem cell
(More)

Related mentions per year

Related mentions per year

1936-2019
19401960198020002020
RAEB with Fibrosis
cancer cell
Bone Marrow
Thrombocytopenia
Anemia
Neoplastic Cell

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Acute myeloid leukemia (AML) is defined as ≥20% myeloblasts, representing a change from original guidelines where ≤30% blasts… (More)
Is this relevant?
2014
2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.
The myelodysplastic syndromes are a heterogeneous group of disorders of the hematopoietic stem cell and stem cell niche. The… (More)
Is this relevant?
2005
2005
Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for myelodysplastic syndrome (MDS). The… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
Is this relevant?
2004
2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
In an attempt to improve the complete remission (CR) rates and to prolong the remission duration especially in elderly patients… (More)
  • table 2
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2000
2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
 Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
The myelodysplastic syndrome (MDS) comprises a group of clonal hematopoietic disorders derived from an abnormality affecting a… (More)
Is this relevant?
1993
1993
Immunotyping of blasts in refractory anaemia with excess of blasts.
A study of immunological markers was performed in 16 patients with newly diagnosed refractory anaemia with excess of blasts (RAEB… (More)
Is this relevant?
1992
1992
Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
Forty-four patients with high risk primary myelodysplastic syndromes and an excess of marrow blasts were treated with a… (More)
Is this relevant?
1991
1991
Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
We treated 47 adult patients with de novo myelodysplastic syndrome (MDS) by an anthracycline-AraC regimen. Median age was 54, and… (More)
Is this relevant?
1989
1989
Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
The toxicity, pharmacokinetics, and hematologic effects of granulocyte-macrophage colony-stimulating (GM-CSF) were studied in a… (More)
Is this relevant?